Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4607 |
Name | biliary tract cancer |
Definition | A hepatobiliary system cancer that results_in malignant growth located_in the gallbladder or located_in the bile duct. |
Source | DiseaseOntology.org |
Alt Ids | DOID:8092 |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
SRC positive | Bosutinib | biliary tract cancer | sensitive | detail... |
SRC positive | Bosutinib + Gemcitabine | biliary tract cancer | sensitive | detail... |
SRC positive | Bosutinib + Cisplatin | biliary tract cancer | sensitive | detail... |
Unknown unknown | Binimetinib | biliary tract cancer | not applicable | detail... |
NRAS mutant | Binimetinib | biliary tract cancer | predicted - sensitive | detail... |
ERBB2 over exp | HER2 CAR-T cells | biliary tract cancer | predicted - sensitive | detail... |
FGFR2 fusion | Futibatinib | biliary tract cancer | predicted - sensitive | detail... |
ERBB2 mutant | Neratinib | biliary tract cancer | predicted - sensitive | detail... |
ERBB2 L755S | Neratinib | biliary tract cancer | no benefit | detail... |
ERBB2 S310F | Neratinib | biliary tract cancer | conflicting | detail... |
ERBB2 T733I | Neratinib | biliary tract cancer | predicted - sensitive | detail... |
ERBB2 V659E | Neratinib | biliary tract cancer | predicted - sensitive | detail... |
ERBB2 V777L | Neratinib | biliary tract cancer | conflicting | detail... |
Unknown unknown | Ramucirumab | biliary tract cancer | not applicable | detail... |
Unknown unknown | PTC-209 | biliary tract cancer | not applicable | detail... |
ERBB2 amp | Pertuzumab + Trastuzumab | biliary tract cancer | predicted - sensitive | detail... |
ERBB2 over exp | Pertuzumab + Trastuzumab | biliary tract cancer | predicted - sensitive | detail... |
ERBB2 act mut | Pertuzumab + Trastuzumab | biliary tract cancer | predicted - sensitive | detail... |
Unknown unknown | Pembrolizumab | biliary tract cancer | not applicable | detail... |
CDKN2A loss | Palbociclib | biliary tract cancer | no benefit | detail... |
CDKN2A mutant | Palbociclib | biliary tract cancer | no benefit | detail... |
Unknown unknown | M7824 | biliary tract cancer | not applicable | detail... |
BRAF V600E | Dabrafenib + Trametinib | biliary tract cancer | sensitive | detail... |
Unknown unknown | Ipilimumab + Nivolumab | biliary tract cancer | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01828034 | Phase Ib/II | Binimetinib + Cisplatin + Gemcitabine | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | Completed | USA | 0 |
NCT01853618 | Phase I | Tremelimumab | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | Completed | USA | 0 |
NCT02034110 | Phase II | Dabrafenib + Trametinib | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Active, not recruiting | USA | CAN | 12 |
NCT02053376 | Phase II | Regorafenib | A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | Completed | USA | 0 |
NCT02091141 | Phase II | Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02105350 | Phase I | Binimetinib + Gemcitabine + Oxaliplatin | A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer | Withdrawn | 0 | |
NCT02151084 | Phase II | Cisplatin + Gemcitabine + Selumetinib | A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | Active, not recruiting | CAN | 0 |
NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | 4 |
NCT02265341 | Phase II | Ponatinib | Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions | Completed | USA | 0 |
NCT02268825 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers | Terminated | USA | 0 |
NCT02451553 | Phase I | Afatinib Capecitabine | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | Recruiting | USA | 0 |
NCT02452970 | Phase II | RRx-001 Cisplatin + Gemcitabine | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) | Terminated | USA | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Active, not recruiting | USA | 8 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Recruiting | USA | CAN | 28 |
NCT02703714 | Phase II | Pembrolizumab + Sargramostim | Pembrolizumab and GM-CSF in Biliary Cancer | Active, not recruiting | USA | 0 |
NCT02711553 | Phase II | Ramucirumab Merestinib Cisplatin + Gemcitabine | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Active, not recruiting | USA | 18 |
NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Recruiting | USA | 0 |
NCT02821754 | Phase Ib/II | Durvalumab + Tremelimumab | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | Recruiting | USA | 0 |
NCT02897375 | Phase I | Cisplatin + Palbociclib Carboplatin + Palbociclib | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03093870 | Phase II | Capecitabine + Varlitinib Capecitabine | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | Active, not recruiting | USA | 10 |
NCT03101566 | Phase II | Cisplatin + Gemcitabine + Nivolumab Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | Active, not recruiting | USA | 0 |
NCT03111732 | Phase II | Capecitabine + Oxaliplatin + Pembrolizumab | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | Active, not recruiting | USA | 0 |
NCT03337087 | Phase Ib/II | Fluorouracil + Leucovorin + MM-398 + Rucaparib | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | Recruiting | USA | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Active, not recruiting | USA | 3 |
NCT03482102 | Phase II | Durvalumab + Tremelimumab | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | Recruiting | USA | 0 |
NCT03639935 | Phase II | Nivolumab + Rucaparib | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum | Recruiting | USA | 0 |
NCT03684811 | Phase Ib/II | Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib | A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Active, not recruiting | USA | 5 |
NCT03768531 | Phase II | Cabiralizumab + Nivolumab Nivolumab | Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer | Withdrawn | 0 | |
NCT03785873 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + Nivolumab | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | Recruiting | USA | 0 |
NCT03833661 | Phase II | M7824 | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | Active, not recruiting | USA | 8 |
NCT03875235 | Phase III | Cisplatin + Gemcitabine Cisplatin + Durvalumab + Gemcitabine | A Global Phase III Study of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) | Recruiting | USA | 16 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Active, not recruiting | USA | 4 |
NCT03991832 | Phase II | Durvalumab + Olaparib | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors | Recruiting | CAN | 0 |
NCT04003896 | Phase II | Abemaciclib | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy | Not yet recruiting | USA | 0 |
NCT04066491 | Phase II | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + M7824 | Gemcitabine Plus Cisplatin With or Without M7824 in Participants With 1L Biliary Tract Cancer (BTC) | Recruiting | USA | 14 |
NCT04163900 | Phase III | Cisplatin + NUC-1031 Cisplatin + Gemcitabine | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer (NuTide:121) | Recruiting | USA | CAN | 13 |
NCT04203160 | Phase Ib/II | Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | Recruiting | USA | 0 |
NCT04466891 | Phase II | ZW25 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers | Recruiting | USA | 4 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Recruiting | USA | CAN | 11 |
NCT04566133 | Phase II | Hydroxychloroquine + Trametinib | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | Not yet recruiting | USA | 0 |